Dystrophic epidermolysis bullosa (DEB): cross-border specialty drug access for international patients

Rare dermatology and pediatric genetics

ICD-10: Q81.2

Quick orientation

Dystrophic epidermolysis bullosa affects an estimated 3 to 6 per million people. The recessive form (RDEB) is the most severe and is often diagnosed in infancy.

Typical age of onset. Congenital. Skin blistering is typically apparent at or shortly after birth.

Severity tiers. RDEB ranges from severe generalized (formerly Hallopeau-Siemens) to milder localized forms. Severe forms cause lifelong wound burden, infection risk, and elevated squamous cell carcinoma risk.

Why specialty drugs for Dystrophic epidermolysis bullosa (DEB) are hard to access internationally

Vyjuvek (beremagene geperpavec), approved by the FDA in 2023, is the first topical gene therapy for DEB. Zevaskyn (prademagene zamikeracel), approved in 2025, is a cell-based gene therapy for chronic wounds. Both are difficult to access internationally; gene therapies require qualified administration and topical gene therapies require cold-chain handling.

Treatments approved by the FDA

Vyjuvek (beremagene geperpavec) — FDA approval: 2023. Mechanism: Topical HSV-1-vectored gene therapy delivering COL7A1. Route: Topical to individual wounds weekly. US WAC ballpark: Approximately USD 24,000 per vial; total annual cost varies by wound burden. Country pricing: UAE · Qatar · Jordan · Bahrain · Lebanon.
Zevaskyn (prademagene zamikeracel) — FDA approval: 2025. Mechanism: Autologous ex vivo gene-edited keratinocyte sheet for chronic wounds. Route: Surgical application of cell sheets. US WAC ballpark: Approximately USD 2.5 million per treatment. Country pricing: Saudi Arabia · Kuwait · Egypt · Jordan · Oman · Lebanon.

Cross-border pathways used for Dystrophic epidermolysis bullosa (DEB)

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

What your physician needs to know

Confirm COL7A1 genotype and subtype classification.
Document wound burden, areas, and chronicity.
Pediatric and adult dermatology specialist co-management is essential.
Vyjuvek requires cold-chain storage and weekly application by trained caregivers.
Zevaskyn requires travel to a qualified surgical center.

Common questions

Can my child receive Vyjuvek at home?

After initial training by a treating dermatologist, weekly application is typically done at home. Cold-chain storage at home is required.

Is Vyjuvek available abroad?

International registration is in early stages.

How is Zevaskyn different?

Zevaskyn is a cell-based surgical product for chronic wounds, administered at qualified centers. Vyjuvek is a topical gene therapy applied weekly.

Will these cure DEB?

Both are intended to support wound healing rather than cure the underlying disease. Long-term data continues to accumulate.

What documents are required?

Genetic confirmation, dermatologist's prescription, wound photographs, and clinical summary.

Who handles the cold chain?

Validated specialty couriers with continuous temperature monitoring.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Dystrophic epidermolysis bullosa (DEB), our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Dystrophic epidermolysis bullosa (DEB)

Reserved for you.